SEOM‑GEM clinical guidelines for cutaneous melanoma (2023)

• Iván Márquez Rodas ^[1] ; Eva Muñoz Couselo ^[2] ; Juan F. Rodríguez Moreno ^[3] ; Ana Mª Arance Fernández ^[4] ; Miguel Ángel Berciano Guerrero ^[5] ; Begoña Campos Balea ^[6] ; Luis de la Cruz Merino ^[7] ; Enrique Espinosa Arranz ^[8] ; Almudena García Castaño ^[9] ; Alfonso Berrocal Jaime ^[10]
  1. [1] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  2. [2] Hospital Vall d’Hebron & Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  3. [3] Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain
  4. [4] Hospital Clínic, Barcelona, Spain
  5. [5] Unidad Intercentros de Oncología. Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Málaga, Spain
  6. [6] Hospital Univ. Lucus Augusti, Lugo, Spain
  7. [7] Cancer Immunotherapy, Biomedicine Institute of Seville (IBIS)/CSIC, Clinical Oncology Department, University Hospital Virgen Macarena and School of Medicine, University of Seville, Seville, Spain
  8. [8] Hospital Univ. La Paz, CIBERONC, Madrid, Spain
  9. [9] Hospital Univ. Marqués de Valdecilla, Santander, Spain
  10. [10] Consorcio Hospital General Univ, Valencia, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2841-2855
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with complete resection, adjuvant—and more recently neoadjuvant—with targeted therapy—BRAF and MEK inhibitors—and immunotherapy—anti-PD-1-based therapies—ofer opportunities to reduce the risk of relapse and distant metastases. For patients with advanced disease not amenable to radical treatment, these treatments ofer an unprecedented increase in overall survival. A group of medical oncologists from the Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines, based on a thorough review of the best evidence available. The following guidelines try to cover all the aspects from the diagnosis—clinical, pathological, and molecular—staging, risk stratifcation, adjuvant therapy, advanced disease therapy, and survivor follow-up, including special situations, such as brain metastases, refractory disease, and treatment sequencing. We aim help clinicians in the decision-making process.